Arrivent Biopharma
AVBP · NASDAQ · Health Care · Pharmaceutical Preparations
Pharmaceutical Preparations company based in Newtown Square, Pa.
Example public filing
Montanova Capital, LLC added to its stake +114K shares
Montanova Capital, LLC added to its stake in Arrivent Biopharma, per its Q2 2026 13F.
- 4.52M
- Shares reported · +114K vs prior quarter
- 2.9%
- Disclosed portfolio weight
- $157M
- Reported value
- Holdings as of
- Jun 30, 2026
- Filed
- Aug 14, 2026
Data as of Oct 11, 2026. A real record from the official source, chosen as the most recent insider trade or, failing that, the most recent filing of another kind; not a recommendation.
On file for AVBP, last 12 months
- 0
- Insider filings
- 0
- Congress trades
- 6
- Fund positions
- 0
- Federal contracts
Records OQRO holds, counted by their date; a 13F position is counted once per quarter it is reported.
Insider buying and selling since 2024
Insiders of Arrivent Biopharma reported 4 open-market purchases and 0 sales since 2024; purchases in 2024.
| Year | Bought | Sold |
|---|---|---|
| 2024 | 4×4 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. The amounts, the people and every filing are in OQRO Pro.
See the full picture with OQRO Pro.
6 records for Arrivent Biopharma in the last 12 months, each linked to its filing. Full histories, the screener, alerts for the companies you follow and Ask OQRO.
Latest disclosures
Secure payment by Stripe. Renews every month until you cancel; cancel anytime from your account. No free trial.
Public previews are free. Full research requires Pro. No free trial.
What this page holds
- Insider trades and planned sales
- Politician trades (House and Senate)
- Fund holdings from 13F filings
- Federal contracts, lobbying and short selling
- Full history and context, with a link to every filing
What OQRO is
OQRO reads the public record for US-listed companies — insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings, and federal contract awards — and puts each one in plain words next to the filing it came from. It describes what was disclosed. It does not give investment advice or tell you what to buy.
Want to see real filings before you pay? The home page shows live ones, free, with the link to each source document.
Questions about Arrivent Biopharma insider trading
Have Arrivent Biopharma insiders bought shares recently?
No open-market purchase by an insider of Arrivent Biopharma was filed in the last 90 days. The latest on record was on Jan 30, 2024.
How often do Arrivent Biopharma insiders buy and sell shares?
Since 2024, Arrivent Biopharma insiders reported 4 open-market purchases and 0 sales on Forms 4 and 5, with purchases in 1 different year, most recently 2024.
Do members of Congress trade AVBP?
No trade in Arrivent Biopharma (AVBP) was disclosed by a member of Congress in the last 12 months.
When does Arrivent Biopharma report its next results?
Arrivent Biopharma's next results are expected on Nov 9, 2026. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.